Figure 2. SIP-SII hampers proliferation and migration of bladder cancer cells in an Akt-dependent manner. (A) Cell viability (MTT) assay results for RT112 and JMSU1 cells treated with negative control siRNA (NC), 5.0 μM SIP-SII, or dual treatment with SIP-SII and Akt siRNA (si-Akt) for 24 h. Cell migration assay results for RT112 cells (B) and JMSU1 cells (C) treated with SIP-SII alone or in combination with si-Akt for 24 h. Representative images at 200x magnification. Data are mean ± SD (error bars) of three experiments performed in triplicate. **P < 0.01 vs. DMSO; n = 3. Western blot analyses of RT112 (D) and JMSU1 (E) cells treated with DMSO, SIP-SII, or the combination of SIP-SII and si-Akt for 24 h.